Virios Therapeutics

$5.15
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.37 (-6.88%) Today
+$0.14 (+2.79%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell VIRI and other stocks, options, and ETFs commission-free!

About VIRI

Virios Therapeutics, Inc. Common Stock, also called Virios Therapeutics, is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of antiviral therapies to treat diseases associated with a viral triggered abnormal immune response including fibromyalgia. It offers IMC-1 a novel, proprietary, fixed dose combination of famciclovir and celecoxib. The company was founded by William L. Pridgen on February 28, 2012 and is headquartered in Alpharetta, GA. The listed name for VIRI is Virios Therapeutics, Inc. Common Stock.

CEO
Greg Duncan
Employees
—
Headquarters
Alpharetta, Georgia
Founded
2012
Market Cap
42.74M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
121.93K
High Today
$5.45
Low Today
$4.70
Open Price
$5.36
Volume
150.96K
52 Week High
$16.71
52 Week Low
$4.60

VIRI Earnings

Q4 FY20
Estimated
— per share
Actual
Expected Mar 19, Pre-Market

You May Also Like

ATAC+
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure